GSK and Moderna Trade Vaccine Patent Licenses

The cross-licensing deal ends one patent fight over mRNA delivery tech while GSK's suit against Pfizer continues.

Updated on Nov. 6, 2026 in Biotech

GSK and Moderna Trade Vaccine Patent Licenses

GSK has settled lawsuits accusing Moderna's COVID-19 and RSV vaccines of patent infringement, and the companies have asked a Delaware federal court to dismiss GSK's US infringement claims with prejudice. The settlement is a completed legal resolution, not a product development, and it involves patent cross-licenses in infectious disease with no payments attached.

Why it matters

The settlement clears a dispute over lipid nanoparticle delivery technology, the fatty-particle system that carries messenger RNA into cells, which underpins both companies' vaccine platforms. It follows a broader pattern in which mRNA vaccine makers have pursued patent claims against one another, and GSK's separate suit against Pfizer and BioNTech remains open.

The evidence is the companies' announced settlement and the patent cross-licenses they granted each other in infectious disease, with the stated terms specifying no payments of any kind. The settlement terms beyond the no-payment provision are undisclosed, and the dispute with Pfizer and BioNTech has not been resolved.

The players

GSK

A British pharmaceutical company whose vaccine portfolio and lipid nanoparticle patents are central to the settled litigation.

Moderna

A US biotechnology company built on messenger RNA platforms, whose Spikevax, mNEXSPIKE and mResvia products were named in the suit.

Pfizer

A US pharmaceutical giant that partners with BioNTech on an mRNA COVID-19 vaccine and remains a defendant in GSK's ongoing patent suit.

BioNTech

A German mRNA-focused biotechnology company that co-develops COVID-19 vaccines with Pfizer and is named in GSK's ongoing lawsuit.

The details

The lawsuits centered on lipid nanoparticles, tiny fat-based bubbles that wrap fragile messenger RNA and carry it into cells so the body can produce a harmless viral protein that trains the immune system. GSK's suit accused Moderna's Spikevax COVID-19 vaccine and its mNEXSPIKE and mResvia products of infringing patents covering that delivery technology. Under the settlement, each company receives a license to the other's patents within infectious disease, so both can keep developing and selling vaccines without the threat of a patent injunction.

Timeline

  1. GSK sued Moderna in 2024 over the lipid nanoparticle technology used in the vaccines.

  2. Moderna settled GSK's US and European patent litigation on October 28, 2025.

  3. On November 6, 2026, the companies announced the settlement and asked the Delaware court to dismiss GSK's US claims.

The Tech Race

Moderna's 2022 patent suit against Pfizer began a series of disputes over mRNA vaccine technology that has now produced a cross-licensing deal in one case. GSK's separate lawsuit against Pfizer and BioNTech, filed earlier in 2024, remains ongoing and will show whether the field settles through licensing or litigation.

The cross-licenses let both companies keep manufacturing their existing vaccines without patent interference in infectious disease, and no payments were disclosed as part of the arrangement. Users of Moderna's vaccines see no direct change from the settlement, while the outcome of GSK's suit against Pfizer and BioNTech will determine whether those vaccines face similar constraints.

The takeaway

The settlement shows mRNA patent disputes can be resolved through cross-licensing without payments, which may set a template for others. Watch whether GSK's pending suit against Pfizer and BioNTech in the same court follows this path or proceeds to a ruling.

Further reading

For more on how these vaccine platforms are being built, see the Biotech section.